Clinical trials
- Rice GP, Incorvaia B, Munari L et al. Interferon in relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev 2001; (4): CD002002.
- Johnson KP, Brooks BR, Cohen JA et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting MS: results of a phase III multicenter, double-blind placebo-controlled trial. Neurology 1995; 45(7): 1268-76.
- Polman CH, O'Connor PW, Havrdova E et al. A randomized, placebo-controlled trial of natalizumab for relapsing forms of MS. N Engl J Med 2006; 354 (9): 899-910.
- Hartung HP, Gonsette R, Konig N et al. Mitoxantrone in progressive MS: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002; 360 (9350): 2018-25.
- Cohen JA, Barkhof F, Comi G et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362(5): 402-15.
Guidelines
- NICE. Management of MS in primary and secondary care. CG8. London, NICE, 2004.
Key text
- Compston A, Confavreux C, Lassmann H et al. McAlpine's Multiple Sclerosis (fourth edition). Churchill-Livingstone, 2006.
This is a comprehensive key text book.
Curriculum
This topic is covered in the GP curriculum in statement 15.7: Neurological problems
Online
Useful online resources are provided by the MS society (www.mssociety.org.uk) and MS Trust (www.mstrust.org.uk), including downloadable free guides for primary care.
Contributed by Dr Oliver Lily, consultant neurologist, Leeds General Infirmary
